Terms: = Prostate cancer AND MTCP1, C6_1B, 4515, ENSG00000214827, GS1-273L24_4 AND Clinical Outcome
370 results:
1. Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.
Tamburo M; Buffettino E; Pepe P; Marletta G; Pepe L; Cosentino S; Ippolito M; Pennisi M; Marletta F
Anticancer Res; 2024 May; 44(5):2205-2210. PubMed ID: 38677723
[TBL] [Abstract] [Full Text] [Related]
2. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
3. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract] [Full Text] [Related]
4. Early response monitoring during [
Neubauer MC; Nicolas GP; Bauman A; Fani M; Nitzsche E; Afshar-Oromieh A; Forrer F; Rentsch C; Stenner F; Templeton A; Schäfer N; Wild D; Chirindel A;
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1185-1193. PubMed ID: 38038755
[TBL] [Abstract] [Full Text] [Related]
5. Early biochemical and radiographic response after one cycle of [
Cytawa W; Hendel R; Tomasik B; Weinzierl FX; Bley T; Jassem J; Schirbel A; Buck AK; Bundschuh RA; Hartrampf PE; Werner RA; Lapa C
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3765-3776. PubMed ID: 37474735
[TBL] [Abstract] [Full Text] [Related]
6. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 prostate cancer Subtypes.
Chappidi MR; Sjöström M; Greenland NY; Cowan JE; Baskin AS; Shee K; Simko JP; Chan E; Stohr BA; Washington SL; Nguyen HG; Quigley DA; Davicioni E; Feng FY; Carroll PR; Cooperberg MR
Eur Urol Oncol; 2024 Apr; 7(2):222-230. PubMed ID: 37474400
[TBL] [Abstract] [Full Text] [Related]
7. Tumor-Induced Osteomalacia in Patients With Malignancy: A Meta-analysis and Systematic Review of Case Reports.
Bouraima F; Sapin V; Kahouadji S; Pickering ME; Pereira B; Bouvier D; Oris C
J Clin Endocrinol Metab; 2023 Oct; 108(11):3031-3040. PubMed ID: 37235783
[TBL] [Abstract] [Full Text] [Related]
8. PSMA-heterogeneity in metastatic castration-resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy.
Derlin T; Riethdorf S; Schumacher U; Lafos M; Peine S; Coith C; Ross TL; Pantel K; Bengel FM
Prostate; 2023 Aug; 83(11):1076-1088. PubMed ID: 37147881
[TBL] [Abstract] [Full Text] [Related]
9. Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant prostate cancer.
Omlin A; Cathomas R; von Amsberg G; Reuter C; Feyerabend S; Loidl W; Boegemann M; Lorch A; Heidenreich A; Tsaur I; Larcher-Senn J; Buck SAJ; Mathijssen RHJ; Jaehde U; Gillessen S; Joerger M
Clin Cancer Res; 2023 May; 29(10):1887-1893. PubMed ID: 36917691
[TBL] [Abstract] [Full Text] [Related]
10. Prevalence of tumour-infiltrating CD103
Zhou Q; Ou Y; Dai X; Chen X; Wu S; Chen W; Hu M; Yang C; Zhang L; Jiang H
Br J Cancer; 2023 Apr; 128(8):1466-1477. PubMed ID: 36759726
[TBL] [Abstract] [Full Text] [Related]
11. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
[TBL] [Abstract] [Full Text] [Related]
12. Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring.
Lilleby W; Seierstad T; Inderberg EM; Hole KH
Int J Cancer; 2023 May; 152(10):2166-2173. PubMed ID: 36715014
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of automated full-body bone metastases delineation methods and their corresponding prognostic power.
Schott B; Weisman AJ; Perk TG; Roth AR; Liu G; Jeraj R
Phys Med Biol; 2023 Jan; 68(3):. PubMed ID: 36580684
[No Abstract] [Full Text] [Related]
14. Comprehensive clinical and Genetic Analysis of
Kirchner K; Gamulin M; Kulis T; Sievers B; Kastelan Z; Lessel D
Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360192
[TBL] [Abstract] [Full Text] [Related]
15. Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.
Kafka M; Burtscher T; Fritz J; Schmitz M; Bektic J; Ladurner M; Horninger W; Heidegger I
World J Urol; 2023 Aug; 41(8):2043-2050. PubMed ID: 36287244
[TBL] [Abstract] [Full Text] [Related]
16. Response to [ 177 Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases.
Zisser L; Yu J; Oszwald A; Wollenweber T; Kretschmer-Chott E; Grubmüller B; Kramer G; Shariat SF; Mitterhauser M; Vraka C; Hacker M; Haug AR; Rasul S
Nucl Med Commun; 2022 Nov; 43(11):1113-1120. PubMed ID: 36120814
[TBL] [Abstract] [Full Text] [Related]
17. Accumulation of copy number alterations and clinical progression across advanced prostate cancer.
Grist E; Friedrich S; Brawley C; Mendes L; Parry M; Ali A; Haran A; Hoyle A; Gilson C; Lall S; Zakka L; Bautista C; Landless A; Nowakowska K; Wingate A; Wetterskog D; Hasan AMM; Akato NB; Richmond M; Ishaq S; Matthews N; Hamid AA; Sweeney CJ; Sydes MR; Berney DM; Lise S; ; Parmar MKB; Clarke NW; James ND; Cremaschi P; Brown LC; Attard G
Genome Med; 2022 Sep; 14(1):102. PubMed ID: 36059000
[TBL] [Abstract] [Full Text] [Related]
18. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
[TBL] [Abstract] [Full Text] [Related]
19. clinical outcome in metastatic prostate cancer after primary radiotherapy.
Moll M; Herrmann H; Zaharie A; Goldner G
Strahlenther Onkol; 2023 Jun; 199(6):536-543. PubMed ID: 35953611
[TBL] [Abstract] [Full Text] [Related]
20. Grade migration and important prognostic factors in a pathology specimen for radical radiotherapy in prostate cancer patients.
Majewski W; Lange D; Stanek-Widera A; Itrych B; Krzysztofiak T; Jarząb M; Oczko-Wojciechowska M; Kajor M; Tarnawski R
Pol J Pathol; 2022; 73(1):27-33. PubMed ID: 35848478
[TBL] [Abstract] [Full Text] [Related]
[Next]
